Pharma and R&D
Transforming Oncology Research with Patient-Derived Microtumor Models
Encapsulate’s Tumor-on-a-Chip platforms delivers rapid, reproducible, and scalable preclinical data.
We help you and your team accelerate pharmaceutical processes and research development.
Core Capabilities
Tumor-on-a-Chip Platforms
Recreate patient-specific tumor microenvironments in a controlled, microfluidic system that preserves 3D architecture, cellular heterogeneity, and stromal interactions.
Patient-Derived Microtumors (PDMs)
Generate functional tumor models directly from patient biopsies—retaining clinically relevant phenotypes and drug sensitivities.
Precision Oncology Enablement
Move beyond genomics alone. Our platform delivers functional response data to complement molecular profiling and improve therapeutic selection.
Automation & Scalability
Standardized workflows and automated systems ensure reproducibility across studies and scalability for pharma pipelines.
Programmable Dosing & Advanced Fluidics
A purpose-built microfluidic biochip that enables programmable dosing, controlled perfusion, and dynamic fluid handling, allowing pharmaceutical companies and research teams to model clinically relevant treatment conditions with greater precision, consistency, and experimental flexibility.
What We Do: Study Types
Patient Stratification Studies
Profile therapeutic response across diverse patient-derived samples to identify responsive subpopulations and support precision medicine strategies.
Efficacy Studies
Profile therapeutic response across diverse patient-derived samples to identify responsive subpopulations and support precision medicine strategies.
Dose Response & Potency Profiling
Define therapeutic response across dose ranges to generate potency curves, compare candidate performance, and inform lead selection.
Resistance Modeling
Characterize intrinsic and acquired resistance mechanisms across patient-derived tumor models to inform next-line strategies and combination design.
Toxicity & Therapeutic Window
Assess on-target and off-target effects in human-relevant tumor systems to better predict clinical tolerability.
Mechanism of Action (MoA)
Interrogate how therapies impact tumor viability, signaling pathways, and cellular interactions.
Combination Screening
Test rational drug combinations to uncover synergistic effects and overcome resistance mechanisms.
Biomarker & Response Correlation
Link functional treatment responses with molecular, histologic, or phenotypic biomarkers to support patient stratification and translational research.
What We Test: Therapeutic Modalities
Standard-of-Care Chemotherapies
Benchmark new candidates against existing treatments.
Targeted Therapies
Evaluate pathway-specific inhibitors in relevant tumor contexts.
Immuno-Oncology Agents
Assess immune-mediated responses in systems that preserve tumor-immune interactions (if applicable—can tweak depending on your capabilities)
Emerging Modalities
Including ADCs, small molecules, and biologics in early-stage pipelines.
Cancer Types Supported
We work with a wide range of solid tumors, including:
- Colorectal cancer (patient derived)
- Pancreatic cancer, PDAC (patient derived)
- Ovarian cancer (patient derived)
- Lung cancer, NSCLC (patient derived and cell line)
- Breast cancer (a variety of cell lines)
- Lymphoma (cell lines)
- Osteosarcoma (cell lines)
- Cervical cancer (cell lines)
- Additional indications based on biopsy availability
If it can be biopsied, we can model it.
What You Get: Data & Deliverables
Actionable Drug Response Data
- Dose-response curves
- IC50 / efficacy metrics
- Responder vs. non-responder stratification
- Comparative performance across therapies or combinations
High-Content Readouts
- Viability and cytotoxicity
- Morphological changes
- Biomarker expression (if applicable)
Dynamic Treatment Response Insights
- Time-course treatment effects
- Response under programmed dosing schedules
- Exposure-response behavior in controlled microfluidic conditions
Translational Insights
- Patient-specific response variability
- Resistance signatures
- Data to support go/no-go decisions
- Biomarker-response correlations
Clear Decision-Ready Reporting
- Delivered in standardized, pharma-ready formats to integrate seamlessly into your R&D workflows., including summary reports, structured datasets, visual outputs, and presentation-ready findings.
How We Partner: Engagement Models
Sample-to-Data
You provide patient biopsies
We generate microtumors and deliver full drug response datasets
Model-to-Data
You provide PDOs or tumor samples
We run studies using our Tumor-on-a-Chip platforms
Drug Testing Partnerships
You provide compounds (SOC or pipeline assets)
We evaluate efficacy across relevant patient-derived models
Custom Study Design
Your provide your program goals
We collaborate to aligned design studies, from early discovery to translational validation
Work with Encapsulate
Partner with Encapsulate to transform your R&D.
Learn how our automated, patient-derived microtumor models can enhance your drug discovery pipeline, deliver scalable screening data, and bring true precision medicine to oncology research.